The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk release_jygqnhtqlza5jo7bhhfyqb62ya

by Gran Walldius

References

NOTE: currently batch computed and may include additional references sources, or be missing recent changes, compared to entity reference list.
Fuzzy reference matching is a work in progress!
Read more about quality, completeness, and caveats in the fatcat guide.
Showing 1 - 30 of 185 references (in 120ms)
[b0]

via grobid
Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione D L, Reeve Jr JR, Young NL. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988; 29:1461-1473.
[b1]

via grobid
Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004; 255(2): 188-205.
[b2]

via grobid
Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy -a review of the evidence. J Intern Med 2006; 259: 493-519.
[b3]

via grobid
Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet 2003; 361: 777-780.
[b4]

via grobid
Walldius G, Jungner I. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoprotein B and A-I -new risk factors and targets for therapy. Nutr Metab Cardiovasc Dis 2007; 17: 565-571.
[b5]

via grobid
Walldius G, Jungner I. ApoB, apoA-I, and the apoB/apoA-I ratio as predictors, markers, and factors for cardiovascular risk. The Fats of Life, LVDD/AACC. www.aacc.org. 2007;
[b6]

via grobid
XXI(1): 11-21.
[b7]

via grobid
Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994; 120: 1012-1025.
[b8]

via grobid
Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med. 2006; 259: 481-492.
[b9]

via fuzzy
Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices
J. H. Contois, J. P. McConnell, A. A. Sethi, G. Csako, S. Devaraj, D. M. Hoefner, G. R. Warnick
2009   Clinical Chemistry
doi:10.1373/clinchem.2008.118356  pmid:19168552 
web.archive.org [PDF]
[b10]

via grobid
Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302(18): 1993-2000. Note also the added supplement.
[b11]

via grobid
Contois JH, Warnick GR, Sniderman AD. Review Article; Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. J Clin Lipidol 2011; 5: 264-272.
[b12]

via grobid
Olofsson SO, Wiklund O, Borén B. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vascular Health and Risk Management 2007; 3(4): 491-502.
[b13]

via grobid
Sniderman A, McQueen M, Contois J, Williams K,. Furberg CD. Why is non-high- density lipoprotein cholesterol a better marker of the risk of vascular disease than low- density lipoprotein cholesterol? Journal of Clinical Lipidology 2010; 4: 152-155.
[b14]

via fuzzy
Non-HDL C equals apolipoprotein B: except when it does not!
Allan Sniderman, Ken Williams, Jacqueline de Graaf
2010   Current Opinion in Lipidology
doi:10.1097/mol.0b013e32833ee80c  pmid:20827192 
[b15]

via grobid
Rader DJ, Davidson M, Caplan RJ, Pears JS. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol 2003; 91(Suppl.): 20C-24C.
[b16]

via grobid
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low- density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
[b17]

via fuzzy
Assessment of Reaching Goal in Patients with Combined Hyperlipidemia: Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, or Apolipoprotein B
Evan A. Stein, Allan Sniderman, Peter Laskarzewski
2005   American Journal of Cardiology
doi:10.1016/j.amjcard.2005.08.006  pmid:16291013 
[b18]

via grobid
Myers GL, Christenson RHM, Cushman M, Ballantyne CM, Cooper GR, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular Disease. Clin Chem 2009; 55: 378- 384.
[b19]

via grobid
Warnick GR. Editors´Notes. Fats of Life, LVDD/ AACC, www.aacc.org. 2010;
[b20]

via grobid
XXIV(3):2- 5, 33-37.
[b21]

via grobid
Sniderman AD, Walldius G, Jungner I. The four horsemen of cholesterol versus ApoB: Good care versus better care. Fats of Life. LVDD/ AACC, www.aacc.org. 2003; XVII(4): 9-24.
[b22]

via grobid
Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G. Errors that result from using the TC/HDL-C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein- related risk of vascular disease. J Intern Med 2006; 259: 455-461.
[b23]

via fuzzy
The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk
Göran Walldius, Ingmar Jungner, Are H. Aastveit, Ingar Holme, Curt D. Furberg, Allan D. Sniderman
2004   Clinical Chemistry and Laboratory Medicine
doi:10.1515/cclm.2004.254  pmid:15576296 
[b24]

via fuzzy
The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations
Hubert Scharnagl, Matthias Nauck, Heinrich Wieland, Winfried März
2001   Clinical Chemistry and Laboratory Medicine
doi:10.1515/cclm.2001.068  pmid:11434393 
[b25]

via grobid
Otvos JD. Why cholesterol measurements may be misleading about lipoprotein levels and cardiovascular disease risk -clinical implications of lipoprotein quantification using NMR spectroscopy. J Lab Med 2002; 26: 544-550.
[b26]

via fuzzy
Non-HDL Cholesterol Shows Improved Accuracy for Cardiovascular Risk Score Classification Compared to Direct or Calculated LDL Cholesterol in a Dyslipidemic Population
H. E. van Deventer, W. G. Miller, G. L. Myers, I. Sakurabayashi, L. M. Bachmann, S. P. Caudill, A. Dziekonski, S. Edwards (+ more)
2011   Clinical Chemistry
doi:10.1373/clinchem.2010.154773  pmcid:PMC4684263  pmid:21228254 
web.archive.org [PDF]
[b27]

via grobid
Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B: III. Comparability of apolipoprotein A-I values by use of International Reference Material. Clin Chem 1993; 39: 773-781.
[b28]

via fuzzy
Non–High-Density Lipoprotein and Very-Low-Density Lipoprotein Cholesterol and Their Risk Predictive Values in Coronary Heart Disease
Jian Liu, Christopher T. Sempos, Richard P. Donahue, Joan Dorn, Maurizio Trevisan, Scott M. Grundy
2006   American Journal of Cardiology
doi:10.1016/j.amjcard.2006.06.032  pmid:17134630 
[b29]

via grobid
Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B: IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 1994; 40: 586-592.
Showing 1 - 30 of 185 references  next »